Graymont and Fortera to Deploy Breakthrough Low-Carbon Cement Technology on a Global Scale
The strategic partnership's objective is to drive the commercialization of a novel low-carbon cement and support the decarbonization of key industries, including building and construction
The agreement will leverage Fortera's carbon mineralization technology with Graymont's calcium-based solutions expertise and its global industrial network
Graymont and Fortera announced they have signed a strategic partnership agreement providing the framework to produce Fortera's ReAct™ low-carbon cement by leveraging Graymont's existing lime production operations and its innovations in sustainable building materials. The partnership reflects years of product testing, design validation, and collaboration between the two companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806499472/en/
The strategic partnership draws on Graymont's global network of manufacturing infrastructure and supply chain to accelerate the deployment of Fortera's technology. The low-carbon cement developed through this partnership is intended for use in all areas where traditional cement is utilized, including infrastructure and construction, as well as industrial processes, without compromising on durability or regulatory compliance. Fortera's ReAct™ low-carbon cement has already undergone over a decade of real-world validation and will now be available at industrial production volumes.
'What stood out to us about Fortera is that they're not trying to reinvent the cement industry. Rather, they're working to innovate on the infrastructure we already have,' said Stéphane Godin, President and CEO at Graymont. 'We've spent more than 75 years building a global calcium solutions business, and this partnership allows us to continue to lead the way in innovative and sustainable products for our customers.'
"Graymont is a global leader, and their decision to partner with us is a strong endorsement for Fortera's technology," said Ryan Gilliam, CEO of Fortera. "From day one, the collaboration with the Graymont team has been instrumental in shaping the commercial design of our plants, from scalability to reliable operations, and in expanding our product opportunities. Together, we're showing that it's possible to cut cement emissions in an economic way."
Fortera's ReAct™ combined with its ReCarb® technology will enable Graymont to expand its production of low-carbon cementitious solutions by reusing CO 2 without significant changes to its facilities or operations, a factor that has traditionally limited the rollout of new technologies.
Fortera is now operating a 15,000-ton-per-year ReCarb® flagship facility in Redding, California. The plant represents a proven bolt-on deployment model that works within existing cement and lime infrastructure, utilizing Fortera's ReCarb® process for the production and distribution of low-carbon cement.
To learn more about how Fortera and Graymont are working together to scale low-carbon cement, visit forteraglobal.com.
About Fortera
Fortera is a pioneering green cement manufacturer with production in Redding, California. Fortera's groundbreaking ReCarb® technology transforms industrial CO 2 into ready-to-use low-carbon cement. ReCarb® seamlessly integrates with current cement facilities, leveraging the entire production framework, from machinery to feedstocks, to ensure a globally scalable solution for sustainable cement manufacturing. The resulting product, Fortera's ReAct™ green cement, is market-ready, meets regulatory standards, and can be blended with or used as a substitute for ordinary cement. For more information on how Fortera is paving the way to zero-CO 2 cement, visit forteraglobal.com.
About Graymont
Graymont is the reliable global leader for essential calcium-based solutions, with more than 75 years in operation. The Company serves a wide range of markets, customers, and communities spanning North America and Asia Pacific. Graymont is also the strategic partner of Grupo Calidra, the largest lime producer in Latin America. Our innovative product offerings are key to the vitality of the industrial, construction, and agricultural sectors. Graymont also provides calcium-based solutions for applications involving critical minerals, air and water purification, as well as the production of indispensable materials such as paper, glass, steel and other metals. For more information, visit Graymont.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806499472/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. 'We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation precision-guided therapeutics that have the potential to help patients live longer and live well,' said Bicycle Therapeutics CEO Kevin Lee, Ph.D. 'We are energized by the progress we are making across our pipeline, and with this momentum, we are pleased to welcome our new Research and Innovation Advisory Board members, as well as new Board member Charles Swanton, to further our innovation and strategic growth.' Dr. Lee continued: 'As we advance our various pipeline programs that hold strong potential for changing the treatment paradigm for patients with cancer and creating value for shareholders, Bicycle remains committed to disciplined capital allocation. Today we announced organizational streamlining efforts that provide us with operational flexibility to deliver potentially value-generating datasets while strengthening our financial position in uncertain market conditions. Saying goodbye to talented team members is very difficult, and we sincerely thank them for their dedication to our company. We believe Bicycle is strongly positioned to realize our strategic priorities and milestones and look forward to providing key program updates over the second half of this year.' Second Quarter 2025 and Recent Events Presented additional human imaging data for an early Bicycle Radioconjugate ® (BRC ®) molecule targeting MT1-MMP at the American Association for Cancer Research (AACR) Annual Meeting 2025. A poster presentation included new data from a second patient who underwent MT1-MMP-PET/CT imaging that build on previously announced data. Altogether, the data continue to validate the potential of MT1-MMP as a novel cancer target and demonstrate the positive properties of BRC molecules for radiopharmaceutical imaging. Imaging data from these two patients are representative of the data generated to date in 12 out of 14 patients with various solid tumors. Bicycle Therapeutics continues to advance its emerging BRC pipeline, with initial EphA2 human imaging data expected in 2H 2025 and company-sponsored clinical trials planned for 2026. Presented two abstracts highlighting the development of Bicycle ® Drug Conjugate (BDC ®) zelenectide pevedotin for metastatic urothelial cancer (mUC) at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. The abstracts outlined previously disclosed topline combination data for zelenectide pevedotin plus pembrolizumab in first-line mUC from the Phase 1/2 Duravelo-1 trial and provided an overview of the ongoing Phase 2/3 Duravelo-2 registrational trial for zelenectide pevedotin in mUC. Bicycle Therapeutics is on track to provide an update on dose selection from the Duravelo-2 trial and the accelerated approval pathway for zelenectide pevedotin in mUC following a meeting with the U.S. Food and Drug Administration planned for 4Q 2025. Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer (NSCLC) open and actively recruiting patients. Duravelo-4 is Bicycle Therapeutics' second trial to leverage NECTIN4 gene amplification as a biomarker for patient selection and to expand the development of zelenectide pevedotin for additional solid tumors. With several trials underway assessing the potential for zelenectide pevedotin to treat mUC, breast cancer and lung cancer, the company has decided to pause the previously announced Phase 1/2 Duravelo-5 trial in multiple tumors. Expanded Board of Directors with the addition of Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, current chair of Bicycle Therapeutics' Clinical Advisory Board. Dr. Swanton leads the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute. His research focuses on how tumors evolve over space and time, developing an understanding of branching evolutionary histories of solid tumors, processes that drive cancer cell-to-cell variation and the impact of cancer diversity on effective immune surveillance and clinical outcomes. Dr. Swanton is a fellow of the Royal Society, a fellow of the Royal College of Physicians and a fellow of the Academy of Medical Sciences. He completed his M.D. and Ph.D. training at the Imperial Cancer Research Fund Laboratories. Formed Research and Innovation Advisory Board (RAB) to support scientific advancement and strategic growth across preclinical programs. The RAB replaces Bicycle's Scientific Advisory Board. Inaugural RAB members include: Jose-Carlos Gutierrez-Ramos, Ph.D., is a director on the Bicycle Therapeutics Board of Directors. He also serves as the chief science officer at Danaher Corporation, leading the Danaher Innovation Centers and the Danaher Scientific Advisory Board. Previously, Dr. Gutierrez-Ramos was head of global drug discovery at AbbVie Inc., group senior vice president of biotherapeutics research and development (R&D) at Pfizer Inc., and senior vice president and CEDD head of immuno-inflammation at GlaxoSmithKline plc. He was also the founding CEO and president of Repertoire Immune Medicine, where he built and led a team focused on decoding the human immunome. Prior to that, he served as president and CEO of Synlogic, Inc. Dr. Gutierrez-Ramos earned a Ph.D. from the immunology department of the Center for Molecular Biology at the Universidad Autonoma de Madrid, and a B.S., summa cum laude, in chemistry with a minor in biochemistry from the Universidad Complutense de Madrid. Jason Lewis, Ph.D., is the Emily Tow Chair at Memorial Sloan Kettering Cancer Center (MSKCC) and currently serves as the deputy director at the Sloan Kettering Institute, overseeing the Office of Scientific Education and Training. He is also the scientific director of the Radiochemistry and Molecular Imaging Probe Core Facility at MSKCC. Dr. Lewis is a laboratory head in Sloan-Kettering Institute's molecular pharmacology program and serves as a professor at the Gerstner Sloan-Kettering Graduate School of Biomedical Sciences and at Weill-Cornell Medical College. He earned a Ph.D. in biochemistry from the University of Kent and an M.S. and B.S. in chemistry from the University of Essex. Robert Lutz, Ph.D., is a consultant/advisor to biotech and pharma with more than 30 years of experience with a significant focus on the development of antibody-drug conjugates (ADCs). He currently serves as chief scientific officer of Iksuda Therapeutics and is a board member and chief development officer of Synthis Therapeutics. Prior to his consulting practice, Dr. Lutz was vice president of translational research and development at ImmunoGen, where he was responsible for the advancement of multiple ADC programs, including KADCYLA ® (ado-trastuzumab emtansine), the first ADC to be approved for solid tumor indications, and ELAHERE ® (mirvetuximab soravtansine). He earned a Ph.D. in biochemistry from Brandeis University and a B.S. in biochemistry from the University of New Hampshire. Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD, is a nuclear medicine physician and professor at the Sir Peter MacCallum Department of Oncology at the University of Melbourne in Australia. His research has been instrumental in advancing PSMA PET imaging and PSMA radioligand therapy, helping to revolutionize the diagnosis and treatment of prostate cancer. He was named Australia's top researcher in nuclear medicine, radiotherapy and molecular imaging in both 2024 and 2025. Professor Hofman leads the PET/CT program and the Prostate Cancer Theranostics and Imaging Centre of Excellence at Peter MacCallum Cancer Centre. He earned a degree in medicine and surgery from Monash University in Australia and undertook a PET/CT fellowship at St. Thomas' Hospital in London. Welcomed Michael Method, M.D., as senior vice president of clinical development. Dr. Method is an academic and clinical gynecologic oncologist with extensive drug development experience. He most recently served as a senior vice president of clinical development at Karyopharm Therapeutics, Inc., after his time as an executive medical director at ImmunoGen, Inc. where he led global clinical development for gynecologic and female malignancies. Previously, Dr. Method was a senior medical advisor for global medical affairs at Eli Lilly, focused on breast cancer. He earned his M.D. and MPH from Northwestern University, and his B.S. in biochemistry and MBA from the University of Notre Dame. Participation in Upcoming Investor Conferences Bicycle Therapeutics management will participate in the following investor conferences in September: Cantor Global Healthcare Conference on Thursday, Sept. 4; fireside chat at 3:55 p.m. ET Morgan Stanley 23 rd Annual Global Healthcare Conference on Tuesday, Sept. 9; fireside chat at 7:45 a.m. ET Live webcasts of the fireside chats will be accessible in the Investor section of the company's website at Archived replays of the webcasts will be available following the fireside chat dates. Second Quarter 2025 Financial Results Cash and cash equivalents were $721.5 million as of June 30, 2025, compared to $879.5 million as of December 31, 2024. The decrease in cash and cash equivalents is primarily due to cash used in operations, including increased cash payments for clinical program activities. R&D expenses were $71.0 million for the three months ended June 30, 2025, compared to $40.1 million for the three months ended June 30, 2024. The increase in expense of $30.9 million was primarily due to increased clinical program expenses for zelenectide pevedotin development, increased discovery, platform and other expenses, and increased personnel-related costs, offset by decreased clinical program expenses for Bicycle Tumor-Targeted Immune Cell Agonist ® (Bicycle TICA ®) molecules as well as higher U.K. R&D tax credits period over period. General and administrative expenses were $18.5 million for the three months ended June 30, 2025, compared to $15.9 million for the three months ended June 30, 2024. The increase in expense of $2.6 million was primarily due to increased personnel-related costs, as well as increased professional and consulting fees. Net loss was $79.0 million, or $(1.14) basic and diluted net loss per share, for the three months ended June 30, 2025, compared to net loss of $39.8 million, or $(0.77) basic and diluted net loss per share, for three months ended June 30, 2024. In recognition of the evolving macroeconomic environment and the importance of preserving capital, Bicycle Therapeutics is implementing a workforce reduction and taking other steps to optimize its operations and extend the company's expected financial runway. These strategic cost realignment efforts are being implemented to prioritize potentially high-impact, value-generating programs, which include the advancement of zelenectide pevedotin, BT5528, next-generation Bicycle ® Drug Conjugates and the company's wholly owned pipeline of Bicycle ® Radioconjugates. Bicycle Therapeutics anticipates total operational savings of approximately 30% over the course of the financial runway period. These actions are expected to extend the financial runway into 2028 and strengthen the company's ability to weather continued market uncertainty as it advances clinical programs through key milestones. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle ® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle ® Drug Conjugate (BDC ®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist ® (Bicycle TICA ®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle ® Radioconjugates (BRC ®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle ® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the validation of MT1-MMP as a cancer target and BRC molecules having positive properties for radiopharmaceutical imaging; the initiation of new clinical trials, the progress of Bicycle's ongoing clinical trials and the timing of EphA2 human imaging data and updates on dose selection in the Duravelo-2 clinical trial and accelerated approval pathway; the outcome of Bicycle's strategic cost realignment efforts and Bicycle's expected financial runway; and the use of Bicycle Therapeutics' technology through various partnerships to develop therapies for diseases beyond oncology. Bicycle Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics' product candidates; the risk that Bicycle Therapeutics may not realize the intended benefits of its cost realignment efforts; the risk that Bicycle's projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle Therapeutics' actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled 'Risk Factors' in Bicycle Therapeutics' Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 1, 2025, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Balance Sheets Data (In thousands) (Unaudited) June 30, December 31, 2025 2024 Cash and cash equivalents $ 721,451 $ 879,520 Working capital 726,840 861,375 Total assets 832,184 956,868 Total shareholders' equity 668,915 793,060 Expand
Yahoo
an hour ago
- Yahoo
Specialty Feed Additives Market worth $21.01 billion by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Aug. 8, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The specialty feed additives market is estimated at USD 16.81 billion in 2025 and is projected to reach USD 21.01 billion by 2030, at a CAGR of 4.6% from 2025 to 2030. Specialty feed additives are estimated to show strong demand in the coming years due to the increasing focus on animal health, feed efficiency, and sustainable production practices in livestock. In recent years, specialty feed additives have been in demand due to their ability to improve nutrient absorption, improve gut health, immune response, and performance of the animal. Specialty additives have precise benefits that improve nutrition or add functionality to the diet. These benefits can include improved digestion, disease resistance, or growth to optimized standards. Products produced with specialty feed additives include enzymes, probiotics, organic acids, and phytogenics. These products are being utilized more in poultry, swine, ruminants, and aquaculture. The market is also experiencing growing consumer demand for natural and antibiotic-free additives due to global regulations eliminating antibiotic growth promoters. This will continue to consider evolving consumer expectations related to safe, quality animal product production during the forecasting columns. Additive production innovation and improved additive formulations targeted to specific species and production outcomes continue to be a factor in supporting the increase in the use of specialty feed additives to move animal production to more efficient and sustainable nutrition practices. Browse in-depth TOC on "Specialty Feed Additives Market" 250 – Tables 60 – Figures 300 – Pages Download PDF Brochure: Poultry feed additives are projected to grow at the highest CAGR among livestock during the forecast period. The poultry livestock sector is leading the way in growth in the specialty feed additives market, owing to continued growth in global poultry production and consumption. The OECD-FAO Agricultural Outlook 2025–2034 notes that poultry meat is projected to make up 62% of global meat production, along with consumption forecasting to reach 173 million tonnes (190.7 million tons) of poultry meat by the year 2034. Poultry is an economical protein source for humans as it allows the most efficient feed conversion, a short production cycle, and a reduced environmental footprint compared to other livestock production. As in many markets such as Asia, Latin America, and the US, the demand for poultry continues to increase, so producers will focus on using specialty feed additives to improve animal health and feed efficiency, as specialty feed additives include organic acids, probiotics, and antioxidants. Issues related to a lack of biosecurity, antibiotic use, and animal welfare are in continuing prominence as functional additives promote improved digestion, immunity, and performance in poultry flocks. The dominance of poultry as the leading protein contributor within the global meat market will continue to develop, and demand for more targeted nutritional solutions in poultry will grow, positioning the sector to become a significant growth segment in the specialty feed additives market. The natural source segment is set to account for a second market share during the forecast period. The natural source segment accounts for a second share in the specialty feed additives market, primarily due to the increasing desire for sustainable and antibiotic-free animal sites. As consumers become increasingly aware of food safety and animal welfare, producers are looking to natural feed additives, including probiotics, prebiotics, phytogenics, and organic acids. These ingredients have been shown to improve gut health, boost immunity, and lessen oxidative stress in livestock. Naturally sourced additives are vulnerable to oxidation and are often priced higher than synthetic additives; however, prominent industry players are making strides in this segment. For instance, in February 2023, Evonik Industries AG (Germany) launched PhytvCare IM, a plant-based additive developed in collaboration with Dr. Eckel, to help reduce inflammation in livestock. Likewise, in November 2022, Layn Natural Ingredients released TruGro MYC, a polyphenol-based approach to dealing with mycotoxin-induced stress in swine and poultry. These developments demonstrate the continuing market opportunities for natural feed additives as strategies for meeting regulatory standards and consumer preferences evolve. Request Sample Pages: European region to hold the second largest market share during the forecast period Europe has an important proportion of the global specialty feed additives market due to better regulatory regimes, advanced livestock farming, and various corporate interests in feed additives such as Nutreco, Evonik Industries AG, and DSM. Regulations on animal health, sustainability, and productivity in Europe have resulted in demand for high-performance additives such as enzymes, probiotics, and amino acids. In September 2023, Novozymes (Denmark) and Bactolife (Denmark) signed a joint development and commercialization agreement to launch Ablacto+, a biosolution targeting post-weaning diarrhea (PWD) in piglets. Ablacto+ uses binding proteins to stabilize piglets' gut health, reducing the need for antibiotics. This collaboration addresses a key challenge in swine health, with potential global impact on antibiotic reduction and improved animal welfare. In February 2023, Evonik launched its first plant-based feed additive for swine, poultry, and ruminants. This plant-extracted feed additive is high in flavonoids and reduces inflammation in dairy cows, laying hens, and sows. Therefore, it enhances their phytogenic-based product portfolio. These developments show Europe's commitment to ensuring innovation and sustainability in feed additives and help entrench Europe's position as a leading global player. The report profiles key players such as Cargill, Incorporated (US), ADM (US), International Flavors & Fragrances Inc. (US), Evonik Industries AG (Germany), BASF SE (Germany), Novonesis Group (Denmark), Adisseo (France), Nutreco (Netherlands), Kemin Industries, Inc. (US), Lallemand Inc. (Canada), and Alltech (US). Get 10% Free Customization on this Report: Browse Adjacent Reports @ Agriculture Industry Market Research Reports & Consulting Related Reports: Feed Additives Market by Livestock, Type (Amino Acids, Probiotics, Vitamins, Acidifiers, Enzymes, Flavors & Sweeteners, Mycotoxin Detoxifiers, Minerals, and Antioxidants), Livestock, Form, Source, Function, and Region - Global Forecast to 2029 Pet Food Ingredients Market Size, Share, Industry Growth Trends Report by Ingredient (Meat & Meat Products Cereals, Vegetables & Fruits Fats, and Additives), Source (Animal-Based, Plant Derivatives, & Synthetic), Pet (Dogs, Cats, and Fish), Form, and Region - Global Forecast to 2028 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets Inc. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Insight: Our Website: Source: Logo: View original content: SOURCE MarketsandMarkets
Business Upturn
5 hours ago
- Business Upturn
Impetus Concludes Successful Plantation Drive Week to Promote Sustainability and Green Living
By Business Wire India Published on August 8, 2025, 10:54 IST Impetus Technologies successfully concluded its Plantation Drive Week, a three-day internal sustainability initiative aimed at fostering environmental awareness and creating a greener campus Business Wire India Impetus Technologies successfully concluded its Plantation Drive Week, a three-day internal sustainability initiative aimed at fostering environmental awareness and creating a greener campus. Held at the Impetus IT Park in Indore, the event witnessed enthusiastic participation from employees across departments, including leadership, with Sanjeev Agrawal, CHRO, Impetus Technologies, setting the tone on Day 1. The drive encouraged employees to actively engage in tree planting efforts, contributing to the company's ongoing environmental goals. 'At Impetus, we believe that building a sustainable future starts with taking responsibility today. The Plantation Drive Week was not just about planting trees, it was about planting hope, awareness, and a collective sense of purpose. I'm proud to see our teams come together with such enthusiasm to contribute to a greener tomorrow, ' said Sanjeev Agrawal, expressing appreciation for the spirited employee involvement throughout the week. The Plantation Drive Week is part of Impetus' broader commitment to environmental responsibility and workplace well-being. With more than 250 saplings planted and a strong message of unity in action, the initiative leaves behind not just greener corners on campus, but also renewed environmental consciousness among the workforce. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
